Skip to content

Alto Neuroscience

US · ANRO #3301 by market cap Listed 2024
25.37 -1.14 -4.30%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 26.50 -0.04%
After-hours 25.37 0.00%
36.6418.2425.372026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on ANRO?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +26.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 14.5% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Operating margin -4,324.8% Better than 1%
Net margin -4,374.8% Better than 1%
Return on equity -41.8% Better than 10%
Return on invested capital -39.2% Better than 8%
Momentum B

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -26.0% Better than 22%
6-month return 19.6% Better than 82%
12-month return (ex latest month) 65.8% Better than 89%
Distance below 52-week high 32.3% Better than 39%
Financial Health B

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 15.7x Better than 97%
Debt to assets 13.0% Better than 65%
Interest coverage -24.6x Better than 9%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 85.3% Better than 80%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -14.12%
1M +3.93%
3M -25.93%
6M +22.09%
YTD +42.53%
1Y +79.29%

Key statistics

Price & volume

Prev close
26.51
Open
25.76
Day range
24.40 - 26.48
Avg price
25.38
Volume
522.54K
Turnover
13.26M
Amplitude
7.85%
52-week range
12.51 - 37.48

Valuation

P/E
-11.58
P/E (TTM)
-10.94
P/B
3.43
EPS
-2.19
Net profit
-87.84M
Net assets
296.54M

Share structure

Market cap
1.02B
Float cap
772.85M
Shares out
40.11M
Float shares
30.46M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2024-02-02
52-week range 52% of range
12.51 37.48

32.3% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-2.17M net over the window

Short interest

Shares short
5.68M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Alto Neuroscience (ANRO)?

Alto Neuroscience last traded at 25.37. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Alto Neuroscience's market cap?

About 1.02B.

What is the P/E ratio of Alto Neuroscience?

The trailing twelve-month P/E is -10.94. The Valuation tab shows it against the stock's own five-year range.

Does Alto Neuroscience pay a dividend?

Alto Neuroscience does not currently pay a regular dividend.

Is Alto Neuroscience a buy according to analysts?

The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 47.00, which implies 85.3% upside from the current price. This is not investment advice.

What is Alto Neuroscience's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Alto Neuroscience a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Alto Neuroscience discussion 0 comments

Add a comment